Abstract: A method of treating or preventing skin yeast infections, such as cutaneous candidiasis, includes applying a polymerizable monomer adhesive composition to an area of skin afflicted with or susceptible to a skin yeast infection, optionally with at least one of an additional anti-fungal agent or a skin care additive, and allowing the polymerizable monomer composition to polymerize to form a polymer film over the area of skin.

Abstract: The present invention relates to graft polymer which is characterized in that it is formed by graft polymerization of structural units containing. a quaternary ammonium group represented by general formula (A), (R2 and R3 each represent an alkyl group with from 1 to 3 carbons, and R4 represents an alkyl group with from 3 to 18 carbons. X represents at least one type of ion selected from halogen, sulphate, hydroxide and carboxylic acid ions.), preferably to graft polymer where the structural units containing a quaternary ammonium group represented by general formula (A) are structural units which are represented by general formula (I), (R1 represents at least one species selected from hydrogen, the methyl group and the ethyl group, and n represents an integer in the range 1 to 12. A represents at least one species selected from O, S and NR5. R5 represents hydrogen or an alkyl group with 1 to 12 carbons.

Abstract: A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam.

Abstract: A cyanoacrylate adhesive is applied onto intact surface skin areas prone to ulceration so as to inhibit formation of surface skin ulcers.

Abstract: The invention relates to a physiologically acceptable composition, especially a cosmetic composition, containing at least one liquid fatty phase comprising at least one fluoro oil, the liquid fatty phase being structured with at least one polymer with a weight-average molecular mass of less than 1,000,000, in particular ranging from 1,000 to 30,000, comprising a) a polymer skeleton having hydrocarbon-based repeating units containing at least one hetero atom, and b) pendent and/or terminal fatty chains that are optionally functionalized, containing from 6 to 120 carbon atoms and being linked to these hydrocarbon-based units, the liquid fatty phase and the polymer forming a physiologically acceptable medium. This composition is especially in the form of a stick of lipstick which, when applied, gives a noteworthy glossy, non-sticky deposit that has good staying power over time and is transfer-resistant.

Abstract: A subject matter of the invention is a composition comprising, in a physiologically acceptable aqueous medium, a wax-in-water emulsion and at least one first polymer with a weight-average molecular mass of less than 100 000 comprising a) a polymer backbone having hydrocarbonaceous repeat units which are provided with at least one amide unit and at least one pendent fatty chain and/or at least one end fatty chain, which fatty chains are optionally functionalized, have from 6 to 120 carbon atoms and are bonded to these amide units.

Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.

Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.

Abstract: The use of polymers comprising as essential structural elements units of the formula I and/or II in which R1 is H, alkyl, cycloalkyl, aryl or aralkyl, R2 and R3 independently of one another are defined as for R1 or are selected from substituted alkyl, substituted cycloalkyl, substituted aryl or substituted aralkyl, the substituents being selected from OH, O-alkyl, O-aryl, SH, S-alkyl, S-aryl, NH2, NH-alkyl, NH-aryl, N(alkyl)2, in protonated form if desired, N(alkyl)3+Z31 , where Z is the radical of an organic or inorganic acid, COOH, COO-alkyl, CONH2, CONH-alkyl, CON(alkyl)2, CN and SO3H; and the indices x in each case independently of one another are an integer from 1 to 20, and their corresponding acid addition salts as biocides.

Abstract: A tablet containing a phosphate-binding polymer, which has an average particle size of 400 &mgr;m or less, contains particles of 500 &mgr;m or less in particle size at a ratio of 90% or more and has a moisture content of 1 to 14%, together with crystalline cellulose and/or low substituted hydroxypropyl cellulose and contains the active component at a high ratio, is excellent in the ability to bind to phosphate, and quickly disintegrates in an acidic to a neutral region.

Abstract: A method for preventing, inhibiting, or treating vaginitis or bacterial vaginosis using polystyrene sulfonate is provided. The polystyrene sulfonate used in the present invention inhibits Trichomonas (a flagellate protozoon), Gardnerella, and other vaginitis/vaginosis-causing bacteria. The method of this invention generally comprises the application of an effective amount of an inhibitory agent into the vagina of a female in need of prevention, inhibition, and/or treatment of vaginitis and/or bacterial vaginosis. Preferably the polystyrene sulfonate in contained in an aqueous based composition, more preferably in an aqueous based composition buffered to a pH of about 3.5 to about 7.5, and even more preferably in an aqueous based composition buffered to a pH of about 3.5 to about 5.

Abstract: A method for treating a microbial infection in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising an amino group or an ammonium group attached to the polymer backbone via an aliphatic spacer group. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.

Abstract: For minimizing Rhus dermatitis a material is used which is topically on a skin and includes an which adsorbs at least a component of an urushiol oil. The material can include of porous hydrophobic divinylbenzene copolymer which initially has surface exposed vinyl groups in which thereafter the vinyl groups are chemically modified so as to form different surface exposed functional groups which hydrophilic and biocompatible.

Abstract: A method for inactivating pathogens is provided. This method generally comprises the application of an effective amount of inhibitory compounds, preferably as a topical formulation, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The inhibitory compounds include a copolymer of maleic acid and styrenesulfonic acid, polyvinyl phthalate sulphate, and their salts. The method can be used for preventing transmission and infection of sexual transmitted diseases, for treating and preventing bacterial vaginitis, and as a contraceptive method. These contraceptives generally have fewer side effects than conventional vaginal contraceptives (e.g., Nonoxynol-9). For example, the compounds useful in the methods of the invention not only are not toxic to natural and beneficial flora and, thus, do not upset the local microbiological balance, but also help maintain a low pH in the vaginal environment.

Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.

Abstract: An assay comprises contacting cells containing a conformationally altered protein with test compound and determining if the altered protein is cleared. The cells may be scrapie-infected neuroblastoma cells. Another assay comprises contacting organ or tissue homogenate (at pH 5.0 or less) with test compound to determine if altered protein in the homogenate is 10 cleared. The homogenate may be brain homogenate from a transgenic mouse infected with human prions. Compounds which are found to clear the altered protein are useful in preventing, arresting and/or reversing (i.e. treating) a disease associated with the conformationally altered protein.

Abstract: A method of forming polymers in the presence of nucleic acid using template polymerization. Also, a method of having the polymerization occur in heterophase systems. These methods can be used for the delivery of nucleic acids, for condensing the nucleic acid, for forming nucleic acid binding polymers, for forming supramolecular complexes containing nucleic acid and polymer, and for forming an interpolyelectrolyte complex.

Abstract: The mechanism of hypertension following acute NO synthase blockage is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a ‘normal’ physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.

Abstract: The invention provides a medical device which comprises a polymer coating. The polymer coating comprises a polymer comprising a polymer backbone and having at least two pendant groups selected from: (a) a polyoxyalkylene ether group, (b) a sulphate group, (c) a sulphonate group, or (d) a sulphamate group, and the polymer is produced by polymerizing monomers having such groups.

Abstract: The present invent relates to sustained release and long residing ophthalmic formulation having thermosensitivity, mucoadhesiveness, hydro gel properties and small particle size.

Abstract: The invention discloses a mammalian teat dip for controlling mastitis, a method for preparing the composition and a method of treatment of mammals. The composition contains a film-forming polymer blend, at least one antimicrobial and a sodium bicarbonate buffering agent. The polymer blend contains a solvent-soluble, thermoplastic polyurethane and a hydrophilic poly(N-vinyl lactam). Upon application to mammalian skin, this composition leaves a long-lasting, water-resistant, residual, elastic film that treats and protects mammalian skin from infection.

Abstract: An ionic polymer is utilized in “recharging” (another layer having a different charge) a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The resulting recharged complex can be formed with an appropriate amount of positive or negative charge such that the resulting complex has the desired net charge.

Abstract: Polymers are provided having a structure selected from: R(—O—R1,)x and R(—NH—R1)x wherein R(—O—)x is a polyol moiety and R(—NH—)x is a polyamine moiety, with the x being between 2 and 10, inclusive, and each R1 independently has the structure: wherein a divalent amino acid moiety with R2 being a covalent bond or having from 1 to 8 carbon atoms, and y and z are between 0 and 10, inclusive, provided that y and z are not both 0; is a divalent dicarboxylic acid moiety in which R3 is an alkylene or cyclolkylene group containing from 1 to about 15 carbon atoms substituted with a total of from 1 to about 10 hydroxyl groups, with at least a portion of the hydroxyl groups being acylated with 3 to 24 carbon atom carboxylic acids; and R4 is a poly(alkylene oxide) having the structure: R5—(R6—O—)a—R6—Q— with R5 selected from 1 to 40 carbon atom alkyl groups, —OH—, &mda

Abstract: Disclosed are methods for treating burns on mammalian skin to reduce the risk of infection and to minimize fluid loss. Specifically, the methods of this invention involve the in situ formation of a polymeric cyanoacrylate film at the site of the burn. The cyanoacrylate film acts as a barrier inhibiting the introduction of pathogens (e.g., bacteria) into the burn area and as a barrier for the loss of fluids.

Abstract: A powder-based solid cosmetic composition is provided having a hardness not greater than 75 as measured by an Asker hardness tester type C1L, a porosity of at least 0.4 and an impact resistance of at least 5. A process is also provided for making the powder-based solid cosmetic composition. The composition according to the present invention has excellent skin feel upon use and is not easily broken.

Abstract: A sterile or non-sterile flavored monomeric adhesive composition includes a flavoring additive and a monomer. The composition can be applied, for example, to skin or the inside of the mouth. A method of making a sterile, flavored adhesive composition includes placing a mixture of a polymerizable adhesive monomer and a flavoring additive in a container, sealing the container, and sterilizing the mixture and the container. The flavored adhesive composition is particularly useful as a medical adhesive and can include 1,1 -disubstituted ethylene monomers, such as &agr;-cyanoacrylates.

Abstract: The present invention provides compositions comprising a first component and a second component, wherein the first component includes at least two polymerizable organic monomers, and wherein the second component includes an oligomer of a polymerizable organic monomer, a plasticizer and an opacificant agent, wherein said composition polymerizes upon contact with an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.

Abstract: The present invention relates to a method of treating a viral infection in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer comprising a plurality of pendant hydrophobic groups and a plurality of pendant acid functional groups. The acid functional groups are connected directly to the polymer backbone or via an aliphatic spacer group of 1 to about 20 atoms in length.

Abstract: A cyanoacrylate adhesive is applied to non-suturable, non-sterile wound surfaces to protect and/or treat such surfaces, to promote wound healing and to retard infection of the wound.

Abstract: Methods for treating diseases associated with toxicity of Apolipoprotein E (“apoE”). Specifically, the present invention relates to new methods for treating a mammal having a condition associated with toxicity of apolipoprotein E cleavage fragments containing residues 130-169, comprising administering to said mammal a pharmacologically effective amount of compound or a pharmaceutically acceptable sale, derivative or fragment thereof to interfere with the receptor-binding site associated with residues 130-169 of the apolipoprotein E molecule in said mammal.

Abstract: An assay comprises contacting cells containing a conformationally altered protein with test compound and determining if the altered protein is cleared. The cells may be scrapie-infected neuroblastoma cells. Another assay comprises contacting organ or tissue homogenate (at pH 5.0 or less) with test compound to determine if altered protein in the homogenate is cleared. The homogenate may be brain homogenate from a transgenic mouse infected with human prions. Compounds which are found to clear the altered protein are useful in preventing, arresting and/or reversing (i.e. treating) a disease associated with the conformationally altered protein.

Abstract: A copolymer having silyl groups with at least one reactive functional group bonded thereto. The copolymer comprises a monomer (A) shown by the following Formula (I): wherein R1 is hydrogen atom or methyl; R2 is alkylene group having 1-6 carbon atoms; and R3, R4 and R5 each is a reactive functional group which can cross-link molecules of the copolymer by hydrolyzing. Further, the copolymer preferably comprises, as a constituent monomer, an alkyl (meth)acrylate and a siloxane-containing (meth)acrylate. A coating-forming method comprises hydrolyzing the composition on a material to be treated to cross-link molecules of the copolymer when on the material. A coating of the cross-linked copolymer has resistance to washing. This coating can modify the nature of hair, improve make-up retention, and provide skin-protecting. It can impart water-repellency, resistance to fouling, suitability as a sizing and crease resistance to fibers.

Abstract: A method of sterilizing objects as well as the sterilized objects obtained from the method are disclosed. The method involves contacting an object such as a medical device to be reused with polycationic dendrimer under conditions which result in rendering a conformationally altered protein (e.g. a prion) non-infectious. A disinfecting agent or surgical scrub composition which comprises the dendrimers is also disclosed as are gelatin capsules treated with polycationic dendrimers.

Abstract: A superporous hydrogel composite is formed by polymerizing one or more ethylenically-unsaturated monomers, and a multiolefinic crosslinking agent, in the presence of particles of a disintegrant and a blowing agent. The disintegrant, which rapidly absorbs water, serves to greatly increase the mechanical strength of the superporous hydrogel and significantly shorten the time required to absorb water and swell. Superporous hydrogel composites prepared by this method have an average pore size in the range of 10 &mgr;m to 3,000 &mgr;m. Preferred particles of disintegrant include natural and synthetic charged polymers, such as crosslinked sodium carboxymethylcellulose, crosslinked sodium starch glycolate, and crosslinked polyvinylpyrrolidone. The blowing agent is preferably a compound that releases gas bubbles upon acidification, such as NaHCO3. Improved hydrogel composites formed without a blowing agent are also provided.

Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.

Abstract: A sustainedly releasing agent for medicines comprising a non-crosslinked type anion-exchange resin represented by the general formula (I): wherein R1 represents aralkyl or alkyl, each of R2 and R3 represents lower alkyl, R4 represents a hydrogen atom or lower alkyl, X− represents a physiologically acceptable counter ion, n represents 1-3, and p represents a mean degree of polymerization, respectively, as well as a sustainedly released medicinal composition comprising the sustainedly releasing agent and a hypolipidemic agent.

Abstract: The present invention relates to a method of treating a viral infection in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer comprising a plurality of pendant hydrophobic groups and a plurality of pendant acid functional groups. The acid functional groups are connected directly to the polymer backbone or via an aliphatic spacer group of 1 to about 20 atoms in length.

Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.

Abstract: The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inibitors, for example, lipstatin and tetrahydrolipstatin.

Abstract: An antimicrobial material is described which can be used to form on the surface on a substrate a non-leaching antimicrobial coating or layer which kills microorganisms on contact. The non-leaching antimicrobial coating or layer is a unique combination of an organic matrix immobilized on the surface of the substrate to having biocidal metallic materials non-leachably associated with the matrix. When a microorganism contacts the coating or layer, the biocidal metallic material is transferred to the microorganism in amounts sufficient to kill it. Methods of applying the coating or layer to a substrate also are provided.

Abstract: Use of polymers which contain (a) 0.1 to 100 mol % of vinylamine units or ethyleneimine units, (b) 0 to 99.9 mol % of units of at least one monomer from the group consisting of open-chain N-vinylcarboxamides, vinyl formate, vinyl acetate, vinyl propionate, vinyl alcohol, C1- to C6-alkyl vinyl ethers, monoethylenically unsaturated C3- to C8-carboxylic acids, their esters, nitriles, amides and anhydrides, N-vinylurea, N-vinylimidazoles and N-vinylimidazolines and (c) 0 to 5 mol % of units of monomers having at least two ethylenically unsaturated double bonds, in copolymerized form, the sum of (a), (b) and (c) in mol % always being 100, as biocide.

Abstract: Disclosed is a series of the water-insoluble polymeric quaternary phosphonium salt-type bactericides, which consists of as active bactericidal components an amino quaternary phosphonium salt, a quaternary ammonium group-containing quaternary phosphonium salt, an amino quaternary phosphonium salt-quaternay ammonium salt, or a quaternary ammonium salt-containing quaternary phosphonium salt and quaternary ammonium salt carried on a resin carrier which can be chloromethylated. Said bactericide series has rapid and highly effective bactericidal activity, and can be used repeatedly, and used widely for sterilizing and disinfecting various fluid media such as different industrial and domestic water and the like.

Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.

Abstract: A method for treating hypercholesterolemia in a patient that includes administering to the patient a therapeutically effective amount of a polydiallylamine polymer.

Abstract: A method of joining together in vivo living tissue surfaces includes (a) holding together at least two tissue surfaces to form abutted tissue surfaces, (b) applying across the abutted tissue surfaces an excessive amount of an adhesive composition comprising at least one monomer that forms a medically acceptable polymer with an applicator having a porous applicator tip; and (c) maintaining the tissue surfaces in contact in vivo until the composition polymerizes to form a thick film of polymerized composition on the abutted tissue surface.

Abstract: The present invention provides a method of arresting, preventing and/or reversing the impairment of central and peripheral nervous system function comprising reducing insoluble protein deposit burden by the administration of branched polycationic compounds and pharmaceutical compositions containing such branched polycationic compounds. The compounds used in the preferred method of the invention are branched dendritic polycations.

Abstract: The present invention relates to a method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a poly(diallylamine) polymer which is substituted with hydrophobic groups. The hydrophobic groups can be a substituted or unsubstituted, straight chain or branched C3-C24-alkyl group, an aralkyl group or an aryl group.

Abstract: A material with excellent selective absorption of super antigens. Said material contains urea bonds or thiourea bonds and remains active even in a high protein concentration solution in the neutral region, Activity remains after sterilization. Also provided is a body fluid purifying column for eliminating or detoxification of super antigens. In addition to that, this invention provides a wound dressing material with super antigen adsorbing properties.